What is Iressa?
Iressa (Gefitinib) is a targeted therapy drug mainly used to treat non-small cell lung cancer (NSCLC). It is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that works by blocking signaling pathways required for the growth and spread of cancer cells. The following is a detailed introduction to Iressa.
1. Basic information about Iressa
| Drug name | Gefitinib |
| Indications | Non-small cell lung cancer (NSCLC) |
| drug class | Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) |
| Dosage form | Tablets (250mg/tablet) |
| Common brands | Iressa (AstraZeneca) |
2. The mechanism of action of Iressa
Iressa inhibits the proliferation and metastasis of cancer cells by inhibiting the tyrosine kinase activity of epidermal growth factor receptor (EGFR) and blocking the signal transduction pathways in cancer cells. EGFR is overexpressed or mutated in a variety of cancers, and Iressa is particularly suitable for patients with EGFR mutation-positive non-small cell lung cancer.
3. Clinical application of Iressa
| Applicable people | EGFR mutation-positive non-small cell lung cancer patients |
| Recommended dosage | 250mg/time, once a day |
| Medication method | Take orally, on an empty stomach or with food |
| treatment cycle | Continue medication until disease progression or intolerable side effects occur |
4. Common side effects of Iressa
The side effects of Iressa are usually mild, but some patients may experience the following adverse reactions:
| Side effect type | Specific performance |
| skin reaction | Rashes, Acne, Dry Skin |
| gastrointestinal reactions | Diarrhea, nausea, vomiting |
| abnormal liver function | Elevated transaminases |
| Eye discomfort | Conjunctivitis, dry eyes |
5. Precautions for Iressa
1.genetic testing: EGFR mutation testing is required before using Iressa to ensure that the patient is suitable for treatment with this drug.
2.Liver function monitoring: Liver function needs to be checked regularly during medication to prevent drug-induced liver damage.
3.avoid pregnancy: Women of childbearing age should take effective contraceptive measures during medication.
4.drug interactions: Iressa may interact with certain drugs (such as CYP3A4 inhibitors or inducers) and should be used with caution.
6. The efficacy and advantages of Iressa
Iressa has shown significant efficacy in patients with EGFR mutation-positive non-small cell lung cancer. Clinical studies have shown that its objective response rate (ORR) can reach 60%-70%, and it can significantly extend progression-free survival (PFS). Compared with chemotherapy, Iressa has milder side effects and a higher quality of life for patients.
7. Market status of Iressa
| Original drug manufacturer | AstraZeneca |
| Domestic launch time | 2005 |
| price range | About 5,000-8,000 yuan/box (prices may vary in different regions) |
| Medical insurance reimbursement | Some areas are included in medical insurance, and the reimbursement ratio varies depending on the policy. |
8. Summary
Iressa is a targeted therapy drug for patients with EGFR mutation-positive non-small cell lung cancer. It has the characteristics of significant efficacy and mild side effects. Patients need to undergo genetic testing before use and take medication under the guidance of a doctor. With the development of precision medicine, targeted drugs such as Iressa will bring hope to more lung cancer patients.
check the details
check the details
en
